Meta-Analysis of Stroke and Mortality Rates in Patients Undergoing Valve-in-Valve Transcatheter Aortic Valve Replacement

Sascha Macherey, MD; Max Meertens, MD; Victor Mauri, MD; Christian Frerker, MD; Matti Adam, MD; Stephan Baldus, MD; Tobias Schmidt, MD

BACKGROUND: During the past decade, the use of transcatheter aortic valve replacement (TAVR) was extended beyond treatment-naïve patients and implemented for treatment of degenerated surgical bioprosthetic valves. Selection criteria for either valve-in-valve (viv) TAVR or redo surgical aortic valve replacement are not well established, and decision making on the operative approach still remains challenging for the interdisciplinary heart team.

METHODS AND RESULTS: This review was intended to analyze all studies on viv-TAVR focusing on short- and mid-term stroke and mortality rates compared with redo surgical aortic valve replacement or native TAVR procedures. A structured literature search and review process led to 1686 potentially relevant studies on July 1, 2020. Finally, 23 studies fulfilled the inclusion criteria for qualitative analysis. All references were case series either with or without propensity score matching and registry analyses. Quantitative synthesis of data from 8509 patients revealed that viv-TAVR is associated with mean 30-day stroke and mortality rates of 2.2% and 4.2%, respectively. Pooled data analysis showed no significant differences in 30-day stroke rate, 30-day mortality, and 1-year mortality between viv-TAVR and comparator treatment (native TAVR [n=11,804 patients] or redo surgical aortic valve replacement [n=498 patients]).

CONCLUSIONS: This review is the first one comparing the risk for stroke and mortality rates in viv-TAVR procedures with native TAVR approach and contributes substantial data for the clinical routine. Moreover, this systematic review is the most comprehensive analysis on ischemic cerebrovascular events and early mortality in patients undergoing viv-TAVR. In this era with increasing numbers of bioprosthetic valves used in younger patients, viv-TAVR is a suitable option for the treatment of degenerated bioprostheses.

Key Words: aortic valve surgery ■ mortality ■ redo aortic valve replacement ■ stroke ■ valve-in-valve transcatheter aortic valve replacement

Transcatheter aortic valve replacement (TAVR) procedures as well as implantation experiences increased rapidly since first TAVR in 2002. Meanwhile, TAVR is a recommended treatment approach in high- and intermediate-risk patients with severe aortic stenosis. The latest randomized trials proved a noninferiority of TAVR even in low-risk patients in comparison to surgical aortic valve replacement (SAVR). During the past decade, the use of TAVR was extended beyond treatment-naïve patients and implemented for treatment of failed surgical bioprosthetic valves. From the surgeon’s perspective, the transcatheter approach remains controversial in these patients in an era with considerable experience in redo SAVR. This knowledge must be weighed against the high procedural risk of redo SAVR in even young and old patients. Selection criteria for either valve-in-valve (viv) TAVR or redo SAVR are not well established, and decision making still remains challenging for the
Macherey et al. Stroke and Mortality Rates Following viv-TAVR

interdisciplinary heart team; this process is based on individual patient characteristics.2,3,11 As peri-interventional mortality and stroke rates are 2 of the most impactful and likely assessable outcomes to judge the safety of the aortic valve replacement (AVR) procedure (either interventional or surgical), this review was intended to analyze all studies on viv-TAVR with respect to these endpoints. This review was intended to be the first one comparing the risk for stroke and mortality rates in viv-TAVR procedures with native AVR approach.

The aim of this meta-analysis was to assess the impact of viv-TAVR on the stroke and mortality rates compared with (a) redo SAVR or (b) native TAVR procedures.

**CLINICAL PERSPECTIVE**

**What Is New?**
- Valve-in-valve transcatheter aortic valve replacement demonstrates comparable or even lower 30-day stroke and mortality rate than redo surgical aortic valve replacement.
- The rate for early stroke and mortality in patients undergoing valve-in-valve transcatheter aortic valve replacement was not even elevated in comparison with a transcatheter aortic valve replacement cohort for native aortic stenosis.

**What Are the Clinical Implications?**
- In selected patients, valve-in-valve transcatheter aortic valve replacement is an appropriate treatment option.

**METHODS**

This meta-analysis was conducted using a prespecified protocol and explicit reproducible plan for literature search and synthesis, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.12 The data that support the findings of this study are available from the corresponding author on reasonable request. The study selection was independently performed by 2 reviewers (S.M. and M.M.). In case of any disagreement, this was resolved by consensus with the senior author (T.S.). We included all trials fitting the following inclusion criteria: case series including at least 10 patients and case-control studies and randomized controlled trials reporting on ischemic cerebrovascular events and mortality after viv-TAVR. Articles published in either German or English were eligible for analysis. Case reports, case series with <10 patients, and publications written in other languages were excluded. Trials with no sufficient report on stroke or mortality data were excluded, too. We performed an electronic search of the bibliographic databases (Medline and Cochrane Database of Systematic Reviews) and hand searching of reference lists. We used the following search terms, “valve-in-valve TAVR,” “valve in valve TAVR,” “valve-in-valve TAVI (transcatheter aortic valve implantation),” “valve in valve TAVI,” “stroke,” “cerebral infarction,” and “embolism,” and connected these terms with Boolean operators.

Stroke incidence after AVR in general was preliminarily defined as primary outcome of this review. We extracted data on the 30-day and 1-year stroke incidence. Secondary end point was death from any cause at 30 days and at 1 year. All data were collected from text, tables, and figures.

We collected the following data from the original trials: first author, year of publication, country, operation period, number of patients enrolled, patients’ age, sex distribution, prosthesis type, prosthesis failure mechanism, study design, Society of Thoracic Surgeons score, stroke rates, and mortality rates.

**Statistical Analysis**

Random-effects meta-analyses were performed using the Mantel-Haenszel method for dichotomous data to estimate pooled risk ratios (RRs) and CIs. Weights were calculated by using Mantel-Haenszel methods. In a further step, the I^2 statistic to quantify possible heterogeneity was calculated (30%<I^2<75%: moderate heterogeneity; I^2>75%: considerable heterogeneity; Review Manager 5.3, Nordic Cochrane Centre, Cochrane Collaboration). We defined P<0.05 as a statistically significant difference. The level of evidence of the original trials was evaluated according to the criteria of the Oxford University.13 To assess the studies’ quality, we judged the individual and overall risk of bias. Initially, we intended to use the risk of bias tool provided by the Cochrane Collaboration, but as we were only able to include nonrandomized and a relevant number of noncontrolled trials, we changed to the ROBINS-I AQ8 (Risk Of Bias In Non-randomized Studies - of Interventions) tool. The application of the ROBINS-I AQ8 tool has been described previously.14 Two reviewers independently judged the risk of bias according to the given criteria (S.M. and M.M.).

**Nonstandard Abbreviations and Acronyms**

| Abbreviation | Description |
|--------------|-------------|
| AVR          | aortic valve replacement |
| SAVR         | surgical aortic valve replacement |
| TAVR         | transcatheter aortic valve replacement |
| viv          | valve in valve |
We did not obtain ethical approval for this meta-analysis because we did not collect data from individual human subjects.

RESULTS
The above search strategy led to 1667 studies in Medline (via PubMed) and 1 reference in the Cochrane Database of Systematic Reviews on July 1, 2020. After meticulous revision of the studies included, we defined 3 subgroups for qualitative and quantitative analyses:

1. Noncomparative case series and registries reporting on the outcome of patients undergoing viv-TAVR.
2. Case series and case-control studies comparing viv-TAVR with redo SAVR.
3. Case series comparing viv-TAVR with native TAVR.

Finally, 23 studies fulfilled the inclusion criteria for qualitative analysis (Figure 1). None of these was a randomized controlled trial. All references were case series either with or without propensity score matching and registry analyses (Tables 1–3). According to the criteria of the Oxford University, these references represent a level of evidence of 4.13 Twelve studies were included in quantitative synthesis.

Noncomparative Case Series and Registries Reporting on the Outcome of Patients Undergoing viv-TAVR
Eleven studies reporting on 8509 patients undergoing viv-TAVR could be included in the statistical analysis of noncomparative case series and registry data (Table 1).\(^{15-25}\) All studies have been published from 2010 to 2019. Surgically implanted bioprostheses had failed in the patients, and mechanisms of failure were regurgitation, stenosis, or both. The patients’ age varied from 74 to 83.9 years, and they had a Society of Thoracic Surgeons score of 6.6% to 21.9%. Data on prior stroke events and history of atrial fibrillation were infrequently reported and heterogeneous. All but 2 studies defined stroke according to the VALVE Academic Research Consortium-2 criteria.\(^{28,31-33}\) Corresponding rates for prior atrial fibrillation or atrial flutter were 32% to 39% and 14% to 39%, respectively.\(^{28,32,33}\) Patients with endocarditis of the aortic valve prosthesis were excluded from the trials. In 3 trials, patients in the open surgery group solely underwent AVR.\(^{28,29,31}\) In the remaining studies, concomitant coronary artery bypass grafting procedure or reconstruction of other valves than the aortic valve was permitted, but not frequently performed. Most patients in the redo SAVR group underwent isolated AVR.\(^{28,32,33}\)

A total of 3 of 226 participants treated with viv-TAVR and 4 of 214 patients undergoing redo SAVR experienced a stroke during the first 30 postoperative days (N=4 trials; RR, 0.86; 95% CI, 0.20–3.59; P=0.83; I\(^2\)=0%; Figure 2A). None of the studies included reported sufficient data on the 1-year stroke incidence.

The 30-day mortality was 4.3% for patients undergoing viv-TAVR and 4.5% for patients undergoing redo SAVR. This difference was not significantly different between both groups (N=6 trials; RR, 0.90; 95% CI, 0.40–2.05; P=0.80; I\(^2\)=0%; Figure 2B). The 1-year mortality rates were 13.3% and 13.6%, respectively (N=2 trials; RR, 0.98; 95% CI, 0.49–1.94; P=0.94; I\(^2\)=0%; Figure 2C).

Case Series Comparing viv-TAVR With Native TAVR
Six studies reporting on 11 804 participants undergoing viv-TAVR (N=4052) and native TAVR (N=7752) were included in statistical analysis (Table 3).\(^{34-39}\) Akodad et al, Huczek et al, and Deharo et al reported prior stroke in 4.1% to 12% of patients undergoing viv-TAVR and 4.7% to 16% of patients undergoing native TAVR.\(^{36,38,39}\) Corresponding rates for prior atrial fibrillation or atrial flutter were 22.9% to 57.9% for viv-TAVR and 21.7% to 57.7% for native TAVR group.\(^{36-39}\) None of the trials reported on anticoagulants used in patients with atrial arrhythmia. Three studies provided data on
The 30-day stroke rate was 1.1% for patients undergoing viv-TAVR and 2.2% for patients undergoing native TAVR (N=5 trials; RR, 0.95; 95% CI, 0.58–1.58; \( P=0.24 \); \( I^2=27\% \); Figure 3A). The stroke events after 1 year were only reported by Akodad et al, and in this cohort, 1 of 49 patients undergoing viv-TAVR and 1 of 83 patients undergoing native TAVR experienced stroke.\(^{38}\) This difference was not statistically significant.\(^{38}\)

A total of 3.2% of patients treated with viv-TAVR and 4.9% of participants undergoing native TAVR died during the first 30 days after operation (N=6 trials; RR, 0.87; 95% CI, 0.58–1.31; \( P=0.10 \); \( I^2=46\% \); moderate heterogeneity; Figure 3B). The corresponding 1-year mortality rates were 7.7% and 13.5%, respectively (N=2 trials; RR, 1.20; 95% CI, 0.51–2.86; \( P=0.68 \); \( I^2=0\% \); Figure 3C).

**DISCUSSION**

**Main Findings**

This systematic review is the most comprehensive analysis on stroke and mortality in patients undergoing
Table 1. Case Series and Registries With viv-TAVR Procedures

| Authors, Studies, Year of Publication | Countries | Operation Period | Patients | viv Prosthesis | Failure Mechanism of Bioprosthesis | Study Design | Median Age, y | Sex: Male Patients, % | STS Score, % | Outcome Definition | 30-d Stroke (Events) | 1-y Stroke (Events) | 30-d Mortality (Events) | 1-y Mortality (Events) |
|--------------------------------------|-----------|-----------------|----------|---------------|-----------------------------------|--------------|-------------|-------------------|--------------|-------------------|-----------------------|-------------------|----------------------|----------------------|
| Kempfert et al, 2010                  | Germany   | 3/2007–12/2009  | 11       | Edwards Sapien | ...                               | Single-center, retrospective case series | 78          | 63.6              | 72              | ...               | ...                   | 0                    | ...                  |
| Pasic et al, 2011                    | Germany   | Since 10/2008   | 14       | Edwards Sapien | Regurgitation and/or stenosis      | Single-center, retrospective case series | 73.3        | 64.3              | 21.9            | ...               | ...                   | 0                    | ...                  |
| Linke et al, 2012                    | Germany   | ...             | 27       | Medtronic: Core Valve | Regurgitation and/or stenosis | Multicentric case series | 74.8        | 70                | ...             | VARC               | 2                     | 2                    |
| Itiberg et al, 2013, Nordic viv registry | Finland, Denmark, Sweden, Norway | 5/2008–1/2012 | 45       | Medtronic: Core Valve, Edwards: Sapien | Regurgitation and/or stenosis | Multicentric, retrospective registry analysis | 80.6*       | 58*               | 15              | VARC               | 1                     | 2                    |
| Duncan et al, 2015                   | United Kingdom | 10/2009–6/2014 | 22       | Medtronic: Core Valve | Regurgitation | Single-center, case series | 74          | 63.6              | 14              | VARC-2              | 0                     | 0                    | 3                    |
| Webb et al, 2017, PARTNER 2          | United States | 1/2012–12/2014 | 365      | Edwards Sapien XT | Regurgitation and/or stenosis | Multicentric, prospective case series | 78.9*       | 64.1              | 9.1*            | VARC-2              | 10                    | 16                   | 10                   | 43                   |
| Ribeiro et al, 2018, VIVID            | Worldwide | 4/2007–5/2016   | 1612     | Mx             | Regurgitation and/or stenosis | Multicentric, retrospective, and prospective registry analysis | 77.8        | 57.9              | 9.5             | VARC-2              | 22/1566               | 74/1545              |
| Schöltz et al, 2018                   | Germany   | 2/2009–12/2016 | 37       | Medtronic: CoreValve, Evolut R | Regurgitation and/or stenosis | Single-center, retrospective case series | 83.9*       | 18.9              | 72              | VARC-2              | ...                   | ...                  | 1                    |
| Huded et al, 2019, STS/AOC registry  | United States | 11/2011–5/2017 | 6147     | Mx             | Regurgitation and/or stenosis | Multicentric, retrospective registry analysis | ...         | ...                | ...             | VARC-2              | 143                   | ...                  | ...                  |
| Ichetché et al, 2019, VIVA registry   | Europe    | ...             | 202      | Medtronic: CoreValve, Evolut R | Regurgitation and/or stenosis | Multicentric, prospective case series/registry | 79.9*       | 47.5              | 6.6*            | VARC-2              | 6                     | 12                   | 5                    | 17                   |
| Starkowski et al, 2019               | Germany   | 1/2010–7/2016  | 27       | Medtronic: CoreValve; Evolut R | ... | Single-center, retrospective case series | 81          | 14.8              | 16.6           | VARC-2              | 0                     | ...                  | 3                    | 0                    |

Pooled data analysis  2.2  4.2

... Indicates data not reported; ACC, American College of Cardiology; PARTNER, Placement of Aortic Transcatheter Valves; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement; TVT, transcatheter valve therapy; VARC, VALVE Academic Research Consortium; viv, valve in valve; and VIVA, valve in valve; VIVID, valve in valve international data.

*Mean instead of median.
| Authors, Studies, Year of Publication | Countries | Operation Period | Patients | vιv Prosthesis | Failure Mechanism of Bioprosthesis | Study Design | Median Age, y | Sex: Male Patients, % | STS Score, % | Outcome Definition | 30-d Stroke (Events) | 1-y Stroke (Events) | 30-d Mortality (Events) | 1-y Mortality (Events) |
|-------------------------------------|-----------|-----------------|----------|----------------|-------------------------------|-------------|--------------|---------------------|---------------|---------------------|---------------------|---------------------|----------------------|----------------------|
| Erlebach et al, 2015               | Germany   | 1/2001–10/2014  | 102      | Mix            | Regurgitation and/or stenosis | Single-center, retrospective case series | vιv: 78.1 rSAVR: 66.2 | vιv: 54 rSAVR: 73 | ...                | VARC-2         | vιv: 2 rSAVR: 1 | ...                | vιv: 2 rSAVR: 0 | ...                |
| Ejiofor et al, 2016               | United States | 1/2002–5/2015  | 44       | Mix            | ...                           | Retrospective case series, bicentric study, propensity-matched analysis | vιv: 75 rSAVR: 74.5 | vιv: 63.6 rSAVR: 59.1 | ...                | vιv: 0* rSAVR: 2* | ...                | vιv: 0 rSAVR: 1 | ...                |
| Santarpino et al, 2016            | Germany   | Since 2010      | 14       | Edwards Sapien, Sapien XT | ...                           | Single-center, retrospective case series | vιv: 80.2 rSAVR: 78.8 | vιv: 66.7 rSAVR: 25 | ...                | ...                | vιv: 0 rSAVR: 0 | ...                | ...                | ...                |
| Silaschi et al, 2017             | Europe    | 2002–2015       | 130      | Mix            | Regurgitation and/or stenosis | Bicentric study, retrospective case-control study | vιv: 78.6 rSAVR: 72.9 | vιv: 57.7 rSAVR: 61 | ...                | VARC-2         | vιv: 0 rSAVR: 2 | ...                | vιv: 3 rSAVR: 3 | ...                |
| Spaziano et al, 2017             | Europe, Canada | 2007–2015      | 156      | Mix            | Regurgitation and/or stenosis | Retrospective case series, bicentric study, propensity-matched analysis | vιv: 78 rSAVR: 77.4 | vιv: 50 rSAVR: 56 | vιv: 7.2 rSAVR: 5.8 | VARC-2         | vιv: 1 rSAVR: 0 | ...                | vιv: 3 rSAVR: 5 | vιv: 9 rSAVR: 10 |
| Grubitzsch et al, 2017           | Germany   | 2010–2015       | 52       | Mix            | Regurgitation and/or stenosis | Retrospective case series | vιv and rSAVR: 72.3 | vιv and rSAVR: 77 | ...                | VARC-2         | vιv: 0 rSAVR: 1 | ...                | vιv: 3 rSAVR: 2 | vιv: 5 rSAVR: 4 |

Within the table, vιv indicates patients treated by vιv-TAVR; and rSAVR, patients treated by rSAVR. ... indicates data not reported; rSAVR, redo surgical aortic valve replacement; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement; VARC, VALVE Academic Research Consortium; and vιv, valve in valve.

*Overall stroke events during follow-up period.

1Stroke rates during in-hospital stay.
| Authors, Studies, Year of Publication | Countries | Operation Period | Patients | viv Prosthesis | Failure Mechanism Bioprosthesis | Study Design | Median Age, y | Sex: Male Patients, % | STS Score, % | Outcome Definition | 30-d Stroke (Events) | 1-y Stroke (Events) | 30-d Mortality (Events) | 1-y Mortality (Events) |
|--------------------------------------|-----------|-----------------|----------|----------------|-------------------|-------------|--------------|------------------|-------------|------------------|-------------------|-----------------|----------------------|---------------------|
| Makkar et al, PARTNER, 2013          | United States | ...             | 2554     | viv: 63 nTAVR: 2491 | Edwards Sapien Regurgitation and/or stenosis | Multicenter study, observational case series | viv: 83.2 nTAVR: 84.5 | viv: 81 nTAVR: 51.6 | viv: 11.4 nTAVR: 11.5 | ... | viv: 3 nTAVR: 81 | ... | viv: 6 nTAVR: 148 | ... |
| Stundl et al, 2016                   | Germany   | 2011–2013       | 141      | viv: 16 nTAVR: 125 | Medtronic Core Valve ... | Single-center study, retrospective case series | viv: 80.1 nTAVR: 80.6 | viv: 68.8 nTAVR: 53.6 | viv: 6.2 nTAVR: 6.3 | ... | viv: 0* nTAVR: 3* | ... | viv: 2 nTAVR: 6 | viv: 4 nTAVR: 27 |
| Huczek et al, 2018, POL-TAVI         | Poland    | 4/2010–5/2016   | 45       | viv: 25 nTAVR: 45 | Mix Regurgitation and/or stenosis | Multicentric, retrospective case series | viv: 65.6/75.6* nTAVR: 80.1 | viv: 55/60 nTAVR: 58 | ... | VARC-2 | ... | viv: 0 nTAVR: 2 | 0 |
| Tuzcu et al, TVT registry, 2018       | United States | 11/2011–6/2016 | 3409     | viv: 1150 nTAVR: 2259 | Mix Regurgitation and/or stenosis | Multicenter study, retrospective case series | viv: 79 nTAVR: 84 | viv: 60.8 nTAVR: 61 | viv: 6.9 nTAVR: 6.8 | ... | viv: 20 nTAVR: 68 | ... | viv: 33 nTAVR: 108 | ... |
| Akodad et al, 2019                   | France    | 2013–2017       | 132      | viv: 49 nTAVR: 83 | Mix Regurgitation and/or stenosis | Bicentric study, retrospective case series | viv and nTAVR: 82.8 | viv and nTAVR: 44.7 | viv and nTAVR: 5.2 | ... | VARC-2 | ... | viv: 1 nTAVR: 1 | viv: 1 nTAVR: 0 | viv: 1 nTAVR: 2 |
| Deharo et al, 2020                   | France    | 2010–2019       | 5498     | viv: 2749 nTAVR: 2749 | Mix Regurgitation and/or stenosis | Multicenter study, retrospective cohort study | viv: 80.75 nTAVR: 80.59 | viv: 49.3 nTAVR: 51.3 | ... | VARC-2 | ... | viv: 18 nTAVR: 14 | ... | viv: 87 nTAVR: 116 | ... |

Within the table, viv indicates patients treated by viv TAVR; and nTAVR, patients treated by nTAVR. ... Indicates data not reported; ACC, American College of Cardiology; nTAVR, first (native) TAVR; PARTNER, Placement of Aortic Transcatheter Valves; POL-TAVI, Polish National TAVI Registry; STS, Society of Thoracic Surgeons; TAVR, transcatheter aortic valve replacement; TVT, transcatheter valve therapy; VARC, VALVE Academic Research Consortium; and viv, valve in valve; VIVA, valve in valve; VIVID, valve in valve international data.

*Stroke rates during in-hospital stay.

†Patients were divided into stentless and stented prosthesis groups.
Macherey et al. Stroke and Mortality Rates Following viv-TAVR

viv-TAVR. Within this article, case series, registries, and trials comparing viv-TAVR with either redo SAVR or native TAVR are included.

Main findings in this review are as follows:

- viv-TAVR is associated with mean 30-day stroke and mortality rates of 2.2% and 4.2%, respectively, based on registry data.
- Quantitative analysis showed no significant differences in 30-day stroke rate, 30-day mortality, and 1-year mortality between viv-TAVR and redo SAVR (Figure 4).
- This review is the first one comparing the risk for stroke and mortality rates in viv-TAVR procedures with native TAVR approach.
- Quantitative analysis showed no significant differences in 30-day stroke rate, 30-day mortality, and 1-year mortality between viv-TAVR and native TAVR.

Agreement and Disagreement With Other Reviews

Four systematic reviews analyzing studies dealing with the outcome of patients undergoing either viv-TAVR or redo SAVR were identified (Table 4).40-43 In conclusion and consistent with the current meta-analysis, there were no significant differences observed in stroke or 30-day mortality rates in these reviews. In comparison with Neupane et al and Gozdek et al, we were able to include additional studies during the review process and statistical analysis.40,42 In distinction to Tam et al and Nalluri et al, we defined the stroke outcome more sensitive by differentiation between 30-day and 1-year event data.41,43 The inclusion of additional studies and the precise methodological approach resulted in a more solid and detailed review.

No other meta-analysis comparing viv-TAVR with native TAVR was identified. This review is the first one comparing
the risk for stroke and mortality rates in these cohorts and contributes substantial data for the clinical routine.

**Clinical Implications**

**Stroke Prevention**

Cerebral embolic events following TAVR might stay silent, but each clinically relevant stroke is meaningful for the individual patient. Stroke was previously described as an independent risk factor for increased mortality following TAVR. Discussions about higher stroke rates for viv procedures are often raised, but larger or randomized studies on stroke rates for viv-TAVR or a comparison to native TAVR procedures is missing. The argument on the stroke incidence often leads to a debate about the need for embolic protection devices.

Studies on cerebral protection were mainly performed for native aortic stenosis and demonstrated that cerebral protection seems to be beneficial in these patients. Predominantly, the filtered debris contained thrombus, valve tissue, aortic wall, or calcification, resulting from structures that were touched during the TAVR procedure. Debris material captured by an embolic protection device during viv-TAVR is similar to the findings after native TAVR procedures. Higher stroke rates following viv-TAVR attributable to friable material from degenerated bioprostheses cannot be concluded from these data. Therefore, on the basis of the stroke rates presented above, the discussion on embolic protection seems not to be different for viv-TAVR than in native TAVR procedures (Figure 3A). The individual patient stroke risk following viv-TAVR might depend on the history of stroke, supraventricular arrhythmia, and cerebrovascular risk factors.

**Surgical Mortality**

The viv-TAVR approach is associated with a low 30-day mortality rate in the current analysis, but as presented above, the use of this technique is restricted to...
several indications. In the original trials analyzed in this systematic review, viv-TAVR was used for treatment of degenerated valves with stenosis, regurgitation, or both. Endocarditis was a contraindication for TAVR approach in the registries and the trials included in this meta-analysis.15-25,28-39

The evidence on operative or early mortality in patients undergoing redo SAVR is mainly based on retrospective series.9,53-55 Overall, the early or operative mortality rates in patients undergoing surgical redo AVR ranged between 5.2% and 6.8%,9,53-55 Mortality rates of <6% were described in studies including younger patients.9,55 In detail, Leontyev et al analyzed a patient cohort with a median age of 58.1 years and Vogt et al reported surgical mortality for a subgroup of patients with a median age of 56 years.9,55

Besides a younger age, elective surgery and other indications than endocarditis were identified as beneficial prognostic factors.9,53 In contrast, the need for aortic root surgery increases the patients’ surgical mortality.9

An immediate transfer of these data from surgical series to the current results is not appropriately feasible as young patients or individuals with aortic disease do not represent the usual viv-TAVR cohort. On the other hand, one might carefully draw the following conclusions from these data:

- Even in an era with increasing number of viv-TAVR procedures, redo SAVR is an irreplaceable approach for selected patients, especially for those experiencing endocarditis or concomitant thoracic aortic disease.
- In patients with the need for reoperation for solely aortic valve prosthesis dysfunction, viv-TAVR offers low early mortality rates in comparison with redo SAVR (Figure 2B).

Current guidelines discuss the implantation of bioprostheses even in younger patients as a therapeutic

Table 4. Results From Other Reviews Comparing TAVR With Redo SAVR

| Studies       | Included Trials | Included Patients | Main Results                                                                 |
|---------------|-----------------|-------------------|-----------------------------------------------------------------------------|
| Neupane et al | 4 trials        | viv-TAVR: N=227   | Overall stroke rate: OR, 1.00; 95% CI, 0.28–3.59; no significant difference |
|               |                 | Redo SAVR: N=262  | 30-d Mortality: OR, 1.08; 95% CI, 0.44–2.62; no significant difference       |
| Tam et al     | 6 trials        | viv-TAVR: N=204   | Overall stroke rate: RR, 0.73; 95% CI, 0.19–3.02; no significant difference |
|               |                 | Redo SAVR: N=192  | 30-d Mortality: RR, 0.78; 95% CI, 0.33–1.84; no significant difference       |
| Gozdek et al  | 5 trials        | viv-TAVR: N=176   | 30-d Stroke rate: RR, 0.62; 95% CI, 0.16–2.42; no significant difference     |
|               |                 | Redo SAVR: N=166  | 30-d Mortality: RR, 1.29; 95% CI, 0.44–3.78; no significant difference       |
| Nalluri et al | 6 trials        | viv-TAVR: N=255   | Overall stroke rate: OR, 0.64; 95% CI, 0.17–2.41; no significant difference |
|               |                 | Redo SAVR: N=339  | 30-d Mortality: OR, 0.97; 95% CI, 0.39–2.39; no significant difference       |

OR indicates odds ratio; RR, risk ratio; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; and viv, valve in valve.
### Table 5. RoB Assessment (ROBINS-I)

| Studies                                      | Confounding          | Selection of Participants | Classification of Interventions | Deviations From Intended Interventions | Missing Data          | Outcome Measurement | Selection of Reported Results |
|----------------------------------------------|----------------------|---------------------------|---------------------------------|----------------------------------------|-----------------------|----------------------|-------------------------------|
| Case Series and Case-Control Studies Comparing viv-TAVR With Redo SAVR |                      |                           |                                 |                                        |                       |                      |                               |
| Erlebach et al, 2015                         | Serious RoB          | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | No sufficient information |
| Ejiofor et al, 2016                         | Moderate RoB         | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | No sufficient information |
| Santarpino et al, 2016                      | Serious RoB          | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | No sufficient information |
| Silauchi et al, 2017                        | Serious RoB          | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | No sufficient information |
| Spaziano et al, 2017                        | Low RoB              | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Low RoB               | Moderate RoB                |
| Grubitzsch et al, 2017                      | Serious RoB          | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | No sufficient information |
| Case Series Comparing viv-TAVR With Native TAVR |                      |                           |                                 |                                        |                       |                      |                               |
| Makkar et al, 2013                          | Serious to moderate RoB | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | Low RoB                      |
| Stundl et al, 2016                          | Critical RoB         | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | No sufficient information |
| Huczek et al, 2018                          | Moderate RoB         | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | No sufficient information |
| Tuzcu et al, 2018                           | Low to moderate RoB  | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | No to low moderate RoB       |
| Akoddad et al, 2019                         | Low to moderate RoB  | Moderate RoB              | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | No sufficient information |
| Deharo et al, 2020                          | Low to moderate RoB  | Moderate to serious RoB   | Moderate RoB                    | Low RoB                                | No sufficient information | Moderate RoB          | Moderate RoB                |

RoB indicates risk of bias; ROBINS-I, Risk Of Bias In Non-randomized Studies - of Interventions; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; and viv, valve in valve.
concept. Consequently, there will be a need of a redo intervention strategy in these patients in the future. viv-TAVR might be a feasible treatment approach in this cohort.

Limitations/Risk of Bias
This systematic review and meta-analysis underlies methodological and content-related limitations. First, only a low level of evidence could be identified. Because randomized controlled trials are still missing, case series or registry data represent the current evidence of cerebrovascular events and mortality in patients undergoing viv-TAVR.

Different strategies were used to minimize the risk of bias during the review process. All published abstracts and full-text articles were considered, but unpublished data (eg, from ongoing trials) were not included. We planned to calculate not only forest, but also funnel plots to assess publication bias. As we did not include the minimum of 10 studies in statistical analysis of any outcome, funnel plot calculation was not appropriately feasible. Nevertheless, we assess the risk of publication bias as moderate to low. Overall, we were able to extract valid data from registries and even data with equal stroke and mortality rates for viv-TAVR and comparator treatment. This does not rule out publication bias, but bearing these data in mind, we suspect only a slight effect.

Moreover, our analysis is affected by a language bias, because we only considered articles published in English and German. Furthermore, this analysis might be affected by a substantial performance bias, because the anticoagulatory treatment during the perioperative and postoperative period was not reported in all studies included. In addition to the nature of a review, the original studies were designed heterogeneously, with potential differences in baseline data, different valve prostheses, different risk profiles (Society of Thoracic Surgeons score), and possible difficult measurable differences in patients’ clinical conditions (Tables 2 and 3). To evaluate the individual risk of bias of each study, we used the ROBINS-I tool, as described in the Methods section. Results are summarized in Table 5. In summary, most studies included comparing viv-TAVR with redo SAVR were uncontrolled case series and resulted in serious to moderate risk of bias in most categories (Table 5). Thoroughly, we rate the overall risk of bias for these studies as “moderate.”

In the evaluation of viv-TAVR versus native TAVR, data from controlled trials (eg, case-control studies with matched pairs) were included. Nevertheless, we judge the overall risk of bias as moderate, because we observed moderate risk of bias for most categories and no sufficient information for management of missing data or selection of reported outcomes in some trials (Table 5).

Finally, we decided to not perform any form of additional testing to address heterogeneity (eg, subgroup or sensitivity analysis) because of low event rates in total.

In addition, a source of detection bias was identified, because 7 trials did not describe the precise definition of stroke (Tables 1–3). To produce reliable data on our research question randomized or at least larger, controlled prospective trials are needed to preserve more valid results.

CONCLUSIONS
Viv-TAVR is an appropriate alternative to redo SAVR, referring to the comparable or even lower 30-day stroke and mortality rate. The rate for early stroke and mortality in patients undergoing viv-TAVR was not even elevated in comparison with a TAVR cohort for native aortic stenosis.

ARTICLE INFORMATION
Received October 6, 2020; accepted January 19, 2021.

Affiliation
From the, Department III of Internal Medicine, University Hospital of Cologne, Cologne, Germany.

Sources of Funding
Open Access funding enabled and organized by ProjektDEAL.

Disclosures
None.

REFERENCES
1. Cribier A, Ettchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme G, Laborde F, Leon MB, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006–3008. DOI: 10.1161/01.CIR.0000047200.36165.B8.
2. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135:e1159–e1195. DOI: 10.1161/CIR.0000000000000503.
3. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Jang JH, Lancellotti P, Lansac E, Rodriguez Muñoz D, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–2791. DOI: 10.1093/eurheartj/ehx391.
4. Mack MJ, Leon MB, Trouiki VH, Maisch E, Kolari M, Siskos R, Mohammad SR, Malaisrie SC, Cohen DJ, Pibarot P, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1696–1705. DOI: 10.1056/NEJMoa1814062.
5. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706–1715. DOI: 10.1056/NEJMoa1816885.
6. Kolkaiah AA, Doukiyy R, Peetelid MF, Vagin AM, Kaneko T, Nahban AF Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk. Cochrane Database Syst Rev. 2019;12:CD013319.
7. Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, Descoutes F, Hengstenberg C, Most NE, Bekeredjian R, et al. Transcatheter aortic valve replacement for degenerative bioprosthetic
Stroke and Mortality Rates Following viv-TAVR

24. Kempert J, Van Linden A, Linke A, Borger MA, Rastan A, Mukherjee C, Ender J, Walther T, Lehmann S, et al. Redo aortic valve surgery: early and late outcomes. Ann Thorac Surg. 2011;91:1120–1126. DOI: 10.1016/j.athoracsur.2010.12.053.

25. Pasic M, Unbehau A, Dreyssé S, BuZ S, Drews T, Kuckuck M, Hetzer R, et al. Transapical aortic valve implantation after previous aortic valve replacement: clinical proof of the “valve-in-valve” concept. J Thorac Cardiovasc Surg. 2011;142:270–277. DOI: 10.1016/j.jtcvs.2010.09.049.

26. Leon MB, Piazza N, Nikolisy E, Blackstone EH, Cutillo DE, Kappetein AP, Krucow MF, Mack M, Mehran R, Miller C, et al. Standardized end-point definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J. 2011;32:205–217. DOI: 10.1093/eurheartj/ehq046.

27. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Detre AP, Dinh DT, de Van Oostra M, et al. Valve-in-valve transcatheter aortic valve implantation: the academic valve research consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012;42:45–60. DOI: 10.1093/ejcts/ezs533.

28. Erlebach M, Wottke M, Deutsch MA, et al. Redo aortic valve surgery versus transcatheter valve-in-valve implantation for failing surgical bioprosthetic valves: consecutive patients in a single-center setting. J Thorac Dis. 2015;7:1944–1950. DOI: 10.3978/j.issn.2072-1439.2015.09.24.

29. Ejofor JI, Yammine M, Harloff MT, McGurk S, Muehlschlegel JD, Shekar PS, Cohn LH, Shah P, Kaneko T, et al. Reoperative aortic valve replacement versus transcatheter valve-in-valve replacement for degenerated bioprosthetic aortic valves. Ann Thorac Surg. 2017;103:580–587. DOI: 10.1016/j.athoracsur.2016.05.086.

30. Santarpino G, Pietsch LE, Jessi J, et al. Transcatheter aortic valve-in-valve implantation and sutureless aortic valve replacement: two strategies for one goal in redo patients. Minerva Cardioangiol. 2016;64:581–585.

31. Silischi M, Wendler O, Seifert M, Castro L, Lubos E, Schirmer J, Blankenberg S, Reischenspurner H, Schäfer U, Treede H, et al. Transcatheter valve-in-valve implantation versus redo surgical aortic valve replacement in patients with failed aortic bioprostheses. Interact Cardiovasc Thorac Surg. 2017;24:63–70. DOI: 10.1093/icvts/ivw200.

32. Spaziano M, Mylotte D, Thériault-Lauzier P, De Backer O, Sonderegger L, Bosmans J, Debry N, Modine T, Barbanti M, Tamburino C, et al. Transcatheter aortic valve implantation versus redo surgery for failing surgical aortic bioprostheses: a multicentre propensity score analysis. EuroIntervention. 2017;13:1149–1156. DOI: 10.4244/EIJ-D-16-00303.

33. Grubitzsch H, Zobel S, Christ T, Holinski S, Stang K, Treskatsch S, Falk V, Laule M, et al. Redo procedures for degenerated stentless aortic xenografts and the role of valve-in-valve transcatheter techniques. Eur J Cardiothorac Surg. 2017;51:653–659. DOI: 10.1093/ejcts/ezs397.

34. Makkar RR, Jialhawi H, Chakravarty T, Fontana GP, Kapadia S, Babbaralors V, Cheng W, Thouari VH, Bavaria J, Svensson L, et al. Determinants and outcomes of acute transcatheter aortic valve therapy or embolization: a study of multiple valve implants in the U.S. PARTNER trial (Placement of AoRTic TranScatheter Valve Trial Edwards SAPIEN Transcatheter Heart Valve). J Am Coll Cardiol. 2013;62:418–430. DOI: 10.1016/j.jacc.2013.04.037.

35. Stundi A, Rademacher M-C, Descoups C, Weber M, Sedaghat A, Grube M, Hammerstingl C, Mellert F, Vasa-Nicotera M, Welz A, et al. Balloon post-dilation and valve-in-valve implantation for the reduction of paravalvular leakage with use of the self-expanding CoreValve prosthesis. EuroIntervention. 2016;11:1140–1147. DOI: 10.4244/EIJY15M11_04.

36. Huczek Z, Grodecki K, Scislo P, Wilczek K, Jagielski D, Fil W, Kubler P, Olzsowka P, Dąbrowski M, Frank M, et al. Transcatheter aortic valve-in-valve implantation in failed stentless bioprostheses. J Interv Cardiol. 2018;31:861–869. DOI: 10.1111/jcic.12540.

37. Tuzcu EM, Kapadia SR, Vempulapalli S, Carroll JJ, Holmes DR, Mack MJ, Thouari VH, Grover FL, Brennan JM, Suri RM, et al. Transcatheter aortic valve replacement of failed surgically implanted bioprostheses: the STS/ACC registry. J Am Coll Cardiol. 2018;71:1709–1716. DOI: 10.1016/j.jacc.2018.04.074.

38. Akobadze M, Meghalac A, LeFevre T, Cayla G, Lattuca B, Autissier C, Duflos C, Gandot M, Tacia J-C, Delensy D, et al. Hemodynamic performances and clinical outcomes in patients undergoing valve-in-valve versus native transcatheter aortic valve implantation. Am J Cardiol. 2019;124:90–97. DOI: 10.1016/j.amjcard.2019.04.009.

39. Dehboor P, Bisson A, Herbert J, Lacour T, Saint Etienne C, Jaussaud N, Theron A, Collart F, Bourguignon T, Guisset T, et al. Valve-in-valve transcatheter aortic valve implantation after failed surgically implanted aortic bioprosthesis versus native transcatheter aortic valve implantation.
for aortic stenosis: data from a nationwide analysis. Arch Cardiovasc Dis. 2020; S1875-2136(20)30108-X. DOI: 10.1016/j.acvd.2020.04.005.

40. Neupane S, Singh H, Lämmer J, Othman H, Yamasaki H, Rosman HS, Bossone E, Mehta RH, Eggebrecht H, et al. Meta-analysis of transcatheter valve-in-valve implantation versus redo aortic valve surgery for bioprosthetic aortic valve dysfunction. Am J Cardiol. 2018;121:1593–1600. DOI: 10.1016/j.amjcard.2018.02.054.

41. Tam DY, Vo TX, Wijeyasurya HC, Dvir D, Friedrich JO, Frenses SE. Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2018;92:1404–1411. DOI: 10.1002/ccd.27686.

42. Gozdzak M, Raffa GM, Suwalski P, Kołodziejczak M, Anisimowicz L, Kubica J, Navarese EP, Kowalewski M, et al. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. Eur J Cardiothorac Surg. 2018;53:495–504. DOI: 10.1093/ejcts/ezx347.

43. Nalluri N, Atti V, Munir AB, Kumar V, Venula P, Edla S, Asti D, Pataru A, et al. Valve in valve transcatheter aortic valve implantation (viv-TAVI) versus redo-surgical aortic valve replacement (redo-SAVR): a systematic review and meta-analysis. J Interv Cardiol. 2018;31:661–671. DOI: 10.1111/jic.12520.

44. Eggebrecht H, Schmermund A, Voigtlander T, Kahler P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention. 2012;8:129–138. DOI: 10.4244/EIJV8I1A20.

45. Kapadia SR, Kodali S, Makkar R, Mehran R, Lazar RM, Zivadinov R, Dwyer MG, Jilaihawi H, Virmani R, Anwaruddin S, et al. Protection against cerebral embolism during transcatheter aortic valve replacement (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention. 2012;8:129–138. DOI: 10.4244/EIJV8I1A20.

46. Haussig S, Mangner N, Dwyer MG, Lehmkuhl L, Lücke C, Wrotzek F, Holzhey DM, Mohr FW, Guterlet M, Zivadinov R, et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA. 2016;316:592–601. DOI: 10.1001/jama.2016.10302.

47. Seeger J, Gonska B, Otto M, Rottbauer W, Wohrle J. Cerebral embolic protection during transcatheter aortic valve replacement significantly reduces death and stroke compared with unprotected procedures. JACC Cardiovasc Interv. 2017;10:2297–2303. DOI: 10.1016/j.jcin.2017.06.037.

48. Lansky AJ, Schofer J, Tchetchine D, Stella P, Petras CG, Parise H, Abrams K, Forrest JK, Cleman M, Reinho J, et al. A prospective randomized evaluation of the TriGuard HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J. 2015;36:2070–2078. DOI: 10.1093/eurheartj/ehv191.

49. Seeger J, Virmani R, Romero M, Gonska B, Rottbauer W, Wohrle J. Significant differences in debris captured by the sentinel dual-filter cerebral embolic protection during transcatheter aortic valve replacement among different valve types. JACC Cardiovasc Interv. 2018;11:1683–1693.

50. Schmidt T, Leon MB, Mehran R, et al. Debris heterogeneity across different valve types captured by a cerebral protection system during transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:1262–1273.

51. Van Mieghem NM, El Faquir N, Rahhab Z, Rodriguez-Olivares R, Wilschut J, Ohlous M, Galema TW, Geleijnse ML, Kappetein A-P, Schipper MEI, et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2015;8:718–724. DOI: 10.1016/j.jcin.2015.01.020.

52. Schmidt T, Schlüter M, Alessandrini H, Akdag O, Schewel D, Schewel J, Thielsen T, Kreidel F, Bader R, Romero M, et al. Histology of debris captured by a cerebral protection system during transcatheter valve-in-valve implantation. Heart. 2016;102:1573–1580. DOI: 10.1136/heartjnl-2016-309597.

53. Jones JMark, O’Kane H, Gladstone DJ, Sarsam MAI, Campaiani G, MacGowan SW, Cleland J, Cran GW, et al. Repeat heart valve surgery: risk factors for operative mortality. J Thorac Cardiovasc Surg. 2001;122:913–918. DOI: 10.1067/mct.2001.116470.

54. Jameson WR, Burr LH, Miyagishima RT, et al. Re-operation for bioprosthetic aortic structural failure - risk assessment. Eur J Cardiothorac Surg. 2003;24:873–878. DOI: 10.1016/S0145-4201(03)00566-9.

55. Vogt PR, Brunner-La Rocca H-P, Sidler P, Zund G, Truniger K, Lachat J, Turina M, Turina MI, et al. Reoperative surgery for degenerated aortic bioprosthesis: predictors for emergency surgery and reoperative mortality. Eur J Cardiothorac Surg. 2000;17:134–139. DOI: 10.1016/S1010-7940(99)00363-2.